IBRX - Company ID 0001326110
ImmunityBio, Inc. trades as IBRX and has a market capitalization of $9.11 B, making it the #1016 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $113.29M, up 668.3% from the prior year and net income of -$351.50M. This page tracks ImmunityBio, Inc. through 528 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years ImmunityBio, Inc.'s revenue grew from $44.00K to $113.29M, a compound annual growth rate of 139.3%. Net profit margin expanded from -274565.9% to -310.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-18 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Major company event | 8-K | 2026-04-09 |
| Major company event | 8-K | 2026-04-06 |
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million | ImmunityBio, Inc.
The largest companies sharing ImmunityBio, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
ImmunityBio, Inc. (IBRX) has a market capitalization of $9.11 B as of 2026-07-09, ranking #1016 among US-listed companies.
ImmunityBio, Inc. reported revenue of $113.29M for fiscal year 2025, an increase of 668.3% year over year.
In its latest fiscal year ImmunityBio, Inc. reported a net loss of $351.50M.